Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. - Wikidata - awgldk - TriplyDB

Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.

Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.

http://www.wikidata.org/entity/Q38033677

about

Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions Low-grade salivary duct carcinoma or low-grade intraductal carcinoma? Review of the literature.An immunohistochemical panel for reliable differentiation of salivary duct carcinoma and mucoepidermoid carcinoma.Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification.AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.Androgen Receptor Signaling in Salivary Gland Cancer.Molecular signature of salivary gland tumors: potential use as diagnostic and prognostic marker.Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.Salivary Duct Carcinoma of the Parotid: Outcomes with a Contemporary Multidisciplinary Treatment Approach.Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process.Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis.Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.

P2860

Q24598710-6E1EB168-14AB-41FD-9BD6-6C8511F087EF Q27692707-3648C7BA-232F-4838-A153-DC53F16273F5 Q33619720-FBED3A82-44DA-45CF-B9A3-82AA566F4B20 Q36273532-AAA067E4-50C2-461C-90BD-317ECCAAA8A0 Q37015111-35ABB5D0-C0C2-4D0B-B1E0-F4E86679447E Q37629545-5A1EF29B-1AFA-4418-8FEF-3BDB247464E6 Q37676074-7A30C41A-12AE-4290-BC83-857F3A45E9B5 Q38492040-1694B4C7-1B15-45A2-A2A5-7AFEC23D2BAA Q38614842-95F20FF3-1C54-4F4C-B25F-A8FBDFDC85E8 Q38776386-733A3ACA-BD62-470D-BF86-548DD784041F Q38869638-E0533972-12D1-49E2-966B-CA6B4BB6DD1F Q39831543-DA9036E6-F37E-4377-8900-CF13E750942F Q41708696-55B60420-C6FA-4B40-91FC-D34F0FD20BAB Q45716219-1C75B168-CB49-4F74-88C1-D2A6D25346F5 Q45996599-89B65A29-8C86-42A5-BF0D-59DDAB4D6494 Q47259493-F21A92B0-F5A2-4547-AA1A-6617031D3D8E Q47859326-CF939D6B-8B73-46EB-BDD3-38B401F66DF1 Q48123633-5B160D65-8E31-4A74-956F-9938630CE686 Q53121949-CC2BA0E9-634C-45CD-9A18-D84BD50F9C71 Q54226554-3FBB9D5C-1AD2-444B-80E0-A7B45C2502D1 Q54997136-039023BC-5357-4546-B84B-7BD61A8591AC Q55452685-AE93C2EE-9649-4387-8E60-483B4ACA94B5

P2860

Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.

http://www.wikidata.org/entity/Q38033677

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Salivary duct carcinomas can b ...... ER2 and basal-like phenotypes.

@en

type

label

Salivary duct carcinomas can b ...... ER2 and basal-like phenotypes.

@en

prefLabel

Salivary duct carcinomas can b ...... ER2 and basal-like phenotypes.

@en

P1433

Q38033677-AD6FFFB8-E49B-4525-9AAC-E50D4AEFC68B

P1476

Q38033677-98C56D35-BB24-426D-BE15-A2EFDF05E5D5

P2093

Q38033677-21B69D01-D67B-4A5C-A8FE-BCE3AA89C903

Q38033677-3EB9E896-69A6-4B07-9854-6687CBED3521

Q38033677-588B75C7-BD54-4DDC-8644-1B3E117EF7A3

Q38033677-85E2A1D4-5A7C-48D0-A3A5-95A5523A55AC

Q38033677-E41973C8-FF06-4C49-9FBA-105332FEBECF

Q38033677-EF26394F-D82F-4C95-B153-B8009AF54C19

Q38033677-EFE20D2D-9B7F-4BD6-83EB-526C3DAD9794

Q38033677-F561A0F7-155C-46A2-A7EC-A8A5B32D9B98

P2860

Q38033677-0108ACF5-16BC-4F29-95B9-498424FEB4BE

Q38033677-02450009-57BE-4C83-9F1F-61A637275126

Q38033677-034D421A-9FE0-46D1-A444-0B2953307492

Q38033677-03C8A8E7-16E3-459F-9B4C-286226861CFC

Q38033677-0B24A5F2-1E88-4746-AD15-CC3F20CAF50B

Q38033677-11476801-FCDB-4D3D-924D-5F9B9038BDA1

Q38033677-11A0EEA3-8AF8-4A17-8AC5-F14C64E2456E

Q38033677-1C3947FE-48A0-489B-A32E-FF64ECBD156D

Q38033677-276C55AF-B2D1-462B-AD27-7A465657A896

Q38033677-29722E35-D583-4822-8F71-349AB4EA664C

P304

Q38033677-8A260302-E31C-4160-8793-3B2B04F5BA46

P31

Q38033677-E46CDB9F-7E14-4020-ADB2-E7A5BE425D1C

P356

Q38033677-61973F48-41C6-4F2E-9DD0-50C494E08CB9

P433

Q38033677-548C12F8-8A62-40D3-BAAC-B93A096C1D7E

P478

Q38033677-79614C03-B0F6-4E3D-B985-C1A3D322E4E1

P50

Q38033677-81C92B49-50A0-4AC7-AED4-002DA17D36B4

P577

Q38033677-8A83A73B-1BB8-4F3F-85F1-C740D92B9927

P698

Q38033677-3434EC06-214F-4682-82A6-D1BAAA4774BF

P356

J.1365-2559.2012.04252.X

P1433

P1476

Salivary duct carcinomas can b ...... ER2 and basal-like phenotypes.

@en

P2093

Alena Skálová

http://www.w3.org/2001/XMLSchema#string

Ann Sandison

http://www.w3.org/2001/XMLSchema#string

Caterina Marchiò

http://www.w3.org/2001/XMLSchema#string

Marco Ungari

http://www.w3.org/2001/XMLSchema#string

Roderick H W Simpson

http://www.w3.org/2001/XMLSchema#string

Silvana Di Palma

http://www.w3.org/2001/XMLSchema#string

Stephen Whitaker

http://www.w3.org/2001/XMLSchema#string

Suzanne Parry

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Triple-Negative Breast Cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

The molecular portraits of breast tumors are conserved across microarray platforms.

Metaplastic breast carcinomas are basal-like tumours.

P304

629-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2559.2012.04252.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Reis-Filho

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22882517

http://www.w3.org/2001/XMLSchema#string